Ditchcarbon
  • Contact
  1. Organizations
  2. Actelion Ltd
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 2 months ago

Actelion Ltd Sustainability Profile

Company website

Actelion Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other rare diseases. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, with core products such as Tracleer, Opsumit, and Uptravi, each designed to improve the quality of life for patients suffering from PAH. Actelion's commitment to research and development sets it apart, as it continually seeks to address unmet medical needs in the industry. With a strong presence in Europe, North America, and Asia, Actelion Ltd. remains a key player in the biopharmaceutical landscape, recognised for its contributions to advancing healthcare solutions.

DitchCarbon Score

How does Actelion Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

77

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Actelion Ltd's score of 77 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.

86%

Let us know if this data was useful to you

Actelion Ltd's reported carbon emissions

Inherited from Johnson & Johnson

Actelion Ltd, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits climate commitments and emissions data from its parent organisation. Actelion's climate initiatives are aligned with those of Johnson & Johnson, which has set ambitious targets for reducing greenhouse gas emissions across its operations. These targets are cascaded down to Actelion at a third-level corporate relationship. However, specific reduction targets or achievements for Actelion itself have not been disclosed. The company is involved in various sustainability initiatives, including participation in the Science Based Targets initiative (SBTi) and the CDP (formerly Carbon Disclosure Project), both of which are led by Johnson & Johnson. These initiatives aim to enhance transparency and accountability in climate action, although specific metrics for Actelion are not provided. In summary, while Actelion Ltd is committed to climate action through its association with Johnson & Johnson, detailed emissions data and specific reduction targets for the company remain unavailable.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

19902006200720082009201020112012201320142015201620172018201920202021202220232024
Scope 1
308,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
751,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
-
-
-
00,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Actelion Ltd's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Actelion Ltd's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Actelion Ltd's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Actelion Ltd is in CH, which has a very low grid carbon intensity relative to other regions.

Actelion Ltd's Scope 3 Categories Breakdown

Actelion Ltd's Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
72%
Upstream Transportation & Distribution
9%
Business Travel
7%
Capital Goods
3%
Employee Commuting
3%
Fuel and Energy Related Activities
2%
Use of Sold Products
2%
End-of-Life Treatment of Sold Products
<1%
Upstream Leased Assets
<1%

Actelion Ltd's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Actelion Ltd has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Actelion Ltd's Emissions with Industry Peers

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Takeda GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated 29 days ago

ISU Abxis Co., Ltd.

KR
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Genzyme Corporation, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 months ago

Salix Pharmaceuticals Ltd.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251209.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy